Claims for Patent: 11,090,300

Summary for Patent: 11,090,300

Title:	Bupropion as a modulator of drug activity
Abstract:	Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Inventor(s):	Herriot Tabuteau
Assignee:	Antecip Bioventures II LLC
Application Number:	US16/822,697
Patent Claims:	1. A method of treating major depressive disorder, comprising orally administering: bupropion, at a daily dose that is about 150 mg to about 250 mg, and dextromethorphan, at a daily dose that is about 60 mg to about 100 mg, to a human being in need thereof for at least 8 consecutive days, wherein the bupropion and the dextromethorphan are orally administered in a dosage form containing both the bupropion and the dextromethorphan as the only therapeutically active compounds, which provides immediate release of dextromethorphan and sustained release of bupropion; and wherein orally administering the dosage form is more effective in treating major depressive disorder than orally administering the same amount of the bupropion alone. 2. The method of claim 1, wherein orally administering the dosage form is more effective in treating major depressive disorder than orally administering the same amount of the dextromethorphan alone. 3. The method of claim 1, wherein the dosage form is orally administered once daily. 4. The method of claim 1, wherein the dosage form is orally administered twice daily. 5. The method of claim 1, wherein the dosage form is orally administered for at least 14 consecutive days. 6. The method of claim 1, wherein the dosage form is orally administered for at least 30 consecutive days. 7. The method of claim 1, wherein the weight ratio of the dextromethorphan to the bupropion in the dosage form is about 0.3 to about 0.5. 8. The method of claim 1, wherein the dosage form is solid. 9. The method of claim 1, wherein on the eighth day the human being has a Cavg of bupropion that is at least about 10 ng/mL after the dosage form is orally administered. 10. The method of claim 1, wherein on the eighth day the human being has a Cmax of bupropion that is at least about 90 ng/mL after the dosage form is orally administered. 11. The method of claim 1, wherein the dosage form comprises a pharmaceutically acceptable excipient. 12. The method of claim 1, wherein the human being is an adult.